Literature DB >> 9590195

High-dose intradialytic urokinase to restore the patency of permanent central vein hemodialysis catheters.

Z J Twardowski1.   

Abstract

From November 1, 1995, to April 30, 1997, in our outpatient dialysis facility, 7,179 or 24.3% of hemodialyses were performed with soft, cuffed, intravenous catheters as blood accesses. Inadequate blood flow (pump speed < 400 mL/min) was noted in 286 instances (4.0%). Locking of catheter lumina with 5,000 to 9,000 IU urokinase was only partly successful in three of 21 cases. Infusions of 20,000 to 40,000 IU urokinase in 25 instances during dialysis restored catheter function in 10 cases. In nine instances in which blood could not be aspirated from the catheter and dialysis could not be performed, the infusion was done through the catheter while the patient remained in the chair. In eight instances, the catheter was opened, and dialysis was performed on the next shift. In 162 instances, a new method was used to open failing catheters most conveniently, efficiently, and with minimal cost. Whenever a nonpositional deterioration of blood flow was noted, 250,000 IU urokinase was infused during dialysis over 3 hours, if there were no contraindications. Full restoration of pump speed was achieved during 132 infusions; in another 21 cases, blood flow improved. In 59 cases, in which an adequate pump speed was not achieved during the next dialysis, the infusion was repeated with restoration of blood flow in 50 instances and flow improvement in six; infusion was re-repeated in the nine instances without complete restoration of flow and in one of the 50 in which restoration of flow was temporary. Adequate flow was restored in nine of these 10 cases in which re-repeated infusion was done. Routine doses of heparin were used concomitantly with urokinase in all cases. No adverse reaction to urokinase has been encountered in any case. To maintain long-term catheter patency, warfarin therapy was started in patients who required repeated urokinase infusions. Vials of 250,000 IU, 9,000 IU, and 5,000 IU urokinase cost $358.47, $77.07, and $43.76, respectively. The higher cost of high-dose intradialytic urokinase as compared with the catheter "lock" is offset by the high probability of positive results, saving of nursing and patient time, and saving on transportation expenses. The convenience and cost are even more remarkably in favor of intradialytic urokinase compared with catheter stripping ($2,433) or surgical replacement ($3,060).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9590195     DOI: 10.1016/s0272-6386(98)70054-x

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  7 in total

1.  Low-intensity adjusted-dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial.

Authors:  Trevor J Wilkieson; Alistair J Ingram; Mark A Crowther; Steven D Soroka; Ryuta Nagai; Kailash K Jindal; Catherine M Clase
Journal:  Clin J Am Soc Nephrol       Date:  2011-04-14       Impact factor: 8.237

2.  Improvement of hemodialysis catheter function with tenecteplase: a phase III, open-label study: TROPICS 4.

Authors:  Steven Fishbane; Samuel L Milligan; Kenneth D Lempert; Joachim E W Hertel; James B Wetmore; Matthew J Oliver; Martha Blaney; Barbara S Gillespie; Joan R Jacobs; Susan M Begelman
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

3.  Thrombolysis for restoration of patency to haemodialysis central venous catheters: a systematic review.

Authors:  C M Clase; M A Crowther; A J Ingram; C S Cinà
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

4.  A review of evolving dialysis catheter technologies.

Authors:  Martha-Grace Knuttinen; Sonia Bobra; Julian Hardman; Ron C Gaba; James T Bui; Charles A Owens
Journal:  Semin Intervent Radiol       Date:  2009-06       Impact factor: 1.513

5.  Central venous lines for chronic hemodialysis: survey of the Midwest Pediatric Nephrology Consortium.

Authors:  Rudolph P Valentini; Denis F Geary; Deepa H Chand
Journal:  Pediatr Nephrol       Date:  2007-11-16       Impact factor: 3.714

6.  Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal replacement therapy for acute renal failure (VERROU-REA study): study protocol for a randomized controlled trial.

Authors:  Rémi Bruyère; Agnès Soudry-Faure; Gilles Capellier; Christine Binquet; Abdelouaid Nadji; Stephane Torner; Gilles Blasco; Maria Yannaraki; Saber Davide Barbar; Jean-Pierre Quenot
Journal:  Trials       Date:  2014-11-19       Impact factor: 2.279

Review 7.  Hemodialysis vascular access options in pediatrics: considerations for patients and practitioners.

Authors:  Deepa H Chand; Rudolph P Valentini; Elaine S Kamil
Journal:  Pediatr Nephrol       Date:  2008-04-08       Impact factor: 3.714

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.